Company intelligence / Profile preview

baCta

Paris, Île-de-France, Francebacta.org.uk ↗

Ownership: Private
Development stage: Preclinical

Overview

baCta has developed a proof-of-concept process using engineered E. coli to produce high-quality, carbon-negative natural rubber from renewable feedstocks. The process removes allergenic proteins found in traditional latex and could be marketed as hypoallergenic. The next milestone is scaling up from milligram lab quantities to pilot-scale industrial output.

Modalities: Microbial therapy (engineered microorganisms)Precision fermentation
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on baCta.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on baCta.

Explore the full profile